ECM
IRLA

Evolution Capital Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Evolution Capital Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-885
Closed -$393K – 61
2022
Q2 		$393K Buy
+885
New +$626K 0.59% 19

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Evolution Capital Management's IRLA Position: Q3 2022 in Review

Evolution Capital Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2022, closing a stake of 885 shares — an estimated $393K sold.

Evolution Capital Management first reported a position in IRLA in Q2 2022 and held it in 1 quarter. The position peaked at $393K in Q2 2022. 58 funds tracked by Wall St. Rank hold IRLA as of Q3 2022.

  • Evolution Capital Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Evolution Capital Management sold 885 IRulya Therapeutics Inc. Common Stock shares in Q3 2022, an estimated $393K.
  • Evolution Capital Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Evolution Capital Management's IRulya Therapeutics Inc. Common Stock position peaked at $393K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2022.

Based on Evolution Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.